November 1, 2024) - Nationally recognized law firm Berger Montague PC informs investors that a lawsuit was filed against Paragon 28, Inc. ("Paragon 28" or the "Company") (NYSE: FNA) on behalf of ...

Independent insurer Paragon Insurance Agency has earned a 2024 Global Recognition Award for achieving $8.2 million in ...

Crescent Biopharma is advancing a drug its CEO claims is “purpose-built” to be a perfected version of Summit Therapeutics’ ...

The immune disease drug developer expects to raise $300 million in a private financing set to close before its combination ...

If you purchased the Paragon 28 common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees ...

Paragon Therapeutics’ spinout Jade Biosciences has entered a reverse merger with Aerovate Therapeutics that will allow Jade to start trading on the Nasdaq. | Paragon Therapeutics’ spinout Jade ...

Elevance Health (NYSE: ELV) recently reported its Q3 results, with revenues exceeding but earnings missing the consensus ...

Antibody maker Paragon Therapeutics has formed another company, this time in the bustling cancer space of PD-1xVEGF, and it will go straight onto the public markets. The new biotech, named ...

Paragon 28, Inc. FNA shares ended the last trading session 7.2% higher at $5.19. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This ...

With its stock down 5.3% over the past week, it is easy to disregard Paragon Care (ASX:PGC). However, the company's fundamentals look pretty decent, and long-term financials are usually aligned with ...

Thanaporn Tantiyanon, Head of Business Unit at Siam Paragon, stated, “Siam Paragon has consistently supported the Thai ...

"People in general are more open to and interested in cocktails that are more balanced, and the Negroni is a paragon of ...